Glimepirida Pensa (Glimepiride)

Glimepirida Pensa is indicated for the management of hyperglycaemia in patients with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

• Improves fasting and post‑prandial blood glucose levels.
• Can be combined with metformin or other oral antidiabetic agents when monotherapy is insufficient.
• May be used in patients who have not achieved glycaemic targets with lifestyle modification alone.
• Suitable for adult patients with preserved pancreatic beta‑cell function.
• Often prescribed when a sulfonylurea class drug is appropriate for the individual's clinical profile.

Glimepirida Pensa may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require prompt medical attention.

Common

• Hypoglycaemia (low blood sugar)
• Nausea or abdominal discomfort
• Headache
• Dizziness or light‑headedness
• Weight gain

Serious

• Severe hypoglycaemia with loss of consciousness
• Allergic reactions such as rash, itching, or swelling
• Hepatic dysfunction indicated by elevated liver enzymes
• Hematologic abnormalities like leukopenia or thrombocytopenia

Before initiating Glimepirida Pensa, clinicians should evaluate patient history and monitor for potential risks.

• Assess renal and hepatic function; dose adjustments may be needed in impairment.
• Use cautiously in elderly patients due to increased hypoglycaemia risk.
• Avoid in patients with a history of sulfonylurea hypersensitivity.
• Monitor blood glucose regularly to detect and manage hypoglycaemia.
• Counsel patients on recognizing symptoms of low blood sugar and appropriate corrective actions.
• Review concomitant use of alcohol, which can potentiate hypoglycaemic episodes.

Glimepirida Pensa can interact with several drug classes, influencing its efficacy or safety profile.

Avoid

• Other sulfonylureas or insulin secretagogues, which may cause additive hypoglycaemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that increase glimepiride plasma levels.
• Disulfiram, which may potentiate hypoglycaemic effects.

Use with caution

• Beta‑blockers, which can mask hypoglycaemia symptoms.
• Thiazide diuretics, potentially enhancing hyperglycaemic effects.
• Corticosteroids, which may reduce glucose‑lowering efficacy.
• Antidepressants such as SSRIs, which have been reported to affect glycaemic control.